ArticleFrontiers in pharmacology2022

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer.

Meng Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.